ImmunoKey develops CAR T-cell therapies focused on treating solid tumors. Their approach aims to overcome the limitations of existing CAR T-cell therapies in solid tumor treatment, offering a potential new avenue for patients.
Funding
Funding not disclosed
Founders
Product
Problem
Existing CAR T-cell therapies have demonstrated limited efficacy in treating solid tumors due to challenges such as poor T-cell infiltration, immunosuppressive tumor microenvironments, and a lack of specific tumor-associated antigens. These limitations hinder the ability of CAR T-cells to effectively target and eliminate solid tumors, resulting in suboptimal patient outcomes.
Solution
ImmunoKey is developing a next-generation CAR T-cell therapy platform, CARKey™, engineered to overcome the challenges associated with treating solid tumors. The CARKey™ platform is designed to enhance T-cell infiltration into the tumor microenvironment, resist immunosuppression, and improve target antigen recognition. This modular platform technology underpins a pipeline of innovative cell therapies aimed at delivering effective and accessible treatments for cancer patients with solid tumors. By addressing the key limitations of current CAR T-cell therapies, ImmunoKey aims to improve patient survival and quality of life.
Target Audience
The primary target audience includes cancer patients with solid tumors who have limited treatment options, as well as clinicians and researchers in the field of oncology and cell therapy.
Features
- CARKey™ modular platform designed to overcome limitations of existing CAR T-cell therapies in solid tumors
- Enhanced T-cell infiltration into the tumor microenvironment
- Resistance to immunosuppression within the tumor microenvironment
- Improved target antigen recognition for specific tumor targeting
- Pipeline of innovative cell therapies based on the CARKey™ platform
- Strategic collaboration with OxTium for AI-driven target discovery